MARKET

ERAS

ERAS

Erasca, Inc.
NASDAQ
14.97
-0.19
-1.25%
After Hours: 15.43 +0.46 +3.07% 19:42 03/27 EDT
OPEN
15.12
PREV CLOSE
15.16
HIGH
15.52
LOW
14.92
VOLUME
3.87M
TURNOVER
--
52 WEEK HIGH
16.41
52 WEEK LOW
1.010
MARKET CAP
4.65B
P/E (TTM)
-34.0769
1D
5D
1M
3M
1Y
5Y
1D
Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't
The Motley Fool · 3d ago
Analysts Conflicted on These Healthcare Names: Erasca (ERAS) and Mereo Biopharma Group Plc (MREO)
TipRanks · 3d ago
Erasca’s HERKULES-3 Trial Reaches Completion: What Investors Should Watch in ERAS-007
TipRanks · 4d ago
Bank of America Securities Reaffirms Their Sell Rating on Erasca (ERAS)
TipRanks · 5d ago
Top performing mid-cap stocks YTD as volatility hits markets
Seeking Alpha · 6d ago
Weekly Report: what happened at ERAS last week (0316-0320)?
Weekly Report · 6d ago
A Look At Erasca (ERAS) Valuation After Its Strong Recent Share Price Rally
Simply Wall St · 03/22 02:05
How Erasca’s Expanded ERAS-0015 License and Narrower 2025 Loss Will Impact Erasca (ERAS) Investors
Simply Wall St · 03/20 16:14
More
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

Webull offers Erasca Inc stock information, including NASDAQ: ERAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ERAS stock methods without spending real money on the virtual paper trading platform.